Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOX | P28300 | 14/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.45 |
| ▸ | MAOA | P21397 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.39 |
| ▸ | BCL2A1 | Q16548 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28652319 | 0.84 | CA2 (0.50) | LOXCA12CA1CA2CA7 | |
| SCHEMBL19259994 | 0.81 | LOX (0.48) | LOXCA12CA1CA2CA7 | |
| SCHEMBL28657408 | 0.79 | LOX (0.52) | LOXCA2LOXL2MAOA | |
| SCHEMBL28663727 | 0.78 | LOX (0.47) | LOXLOXL2MAOA | |
| SCHEMBL19274445 | 0.77 | LOX (0.42) | LOXCA12CA1CA2CA7 | |
| SCHEMBL31012108 | 0.77 | CA2 (0.75) | CA12CA1CA2CA7CA13 | |
| SCHEMBL28663650 | 0.75 | LOX (0.57) | LOXLOXL2 | |
| SCHEMBL28649544 | 0.75 | LOX (0.44) | LOXLOXL2MAOALMNA | |
| SCHEMBL28657374 | 0.75 | LOX (0.68) | LOXCA2LOXL2 | |
| SCHEMBL28643866 | 0.73 | LOX (0.76) | LOXLOXL2MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109311839-B | Methylamine derivatives as lysyl oxidase inhibitors for the treatment of cancer | 癌症研究协会皇家癌症医院 | 2021-11-02 | — | — | CN | disclosed |